Alumis' Envudeucitinib Shows Promising Phase 3 Results in Psoriasis Trials

Alumis Inc. (ALMS) has reported significant results from its Phase 3 ONWARD clinical trials for envudeucitinib, a TYK2 inhibitor aimed at treating moderate to severe plaque psoriasis. The trials met their co-primary endpoints, with 74% of participants achieving at least a 75% improvement in symptoms, as measured by the Psoriasis Area and Severity Index (PASI), at Week 16. Additionally, 65% of patients reached a PASI 90 score, indicating a 90% improvement, and over 40% achieved PASI 100, which signifies complete skin clearance, by Week 24. These results were presented in a recent SEC filing and have led to a substantial increase in Alumis' stock price, which more than doubled in premarket trading.

Fierce BiotechAlumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week highInvestor's Business DailyNasdaq

Envudeucitinib's performance appears to surpass that of Bristol Myers Squibb's (BMS) Sotyktu and Amgen's Otezla. In BMS' trials, PASI 75 response rates were reported at 53% to 58% at Week 16, with PASI 90 rates ranging from 32% to 42%. Furthermore, only 10% to 14% of patients in the Sotyktu studies achieved PASI 100. Alumis CEO Martin Babler noted that the results align with expectations set during an investor event, indicating a competitive edge for envudeucitinib in the psoriasis market.

Fierce BiotechAlumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week highInvestor's Business DailyNasdaq

Alumis plans to file for FDA approval in the latter half of 2026, which could intensify competition for Sotyktu, a drug that generated $206 million for BMS in the first nine months of 2025 but has not met prelaunch expectations. The psoriasis treatment market is characterized by its size and fragmentation, suggesting that multiple effective products can coexist. Alumis aims to emphasize the efficacy, safety, and convenience of envudeucitinib as it seeks to establish its presence in this competitive landscape.

Fierce Biotech

Despite the promising results, there are concerns regarding the durability of envudeucitinib's effects and potential side effects as its use expands. Analysts, including Thomas Smith from Leerink Partners, have highlighted that while the drug shows potential for class-leading TYK2 inhibition, the path to regulatory approval and market entry may not be straightforward. Safety concerns and competitive pricing pressures could impact the drug's launch and market access.

Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

• “the full promise of TYK2 inhibition,” — Jörn Drappa, Chief Medical Officer, Alumis

Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

• “a new oral drug for psoriasis,” — Andrew Blauvelt, Dermatologist

Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

• “pipeline-in-a-pill.” — Martin Babler, CEO, Alumis

Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

While the Phase 3 trials showed strong efficacy for envudeucitinib, the absence of detailed results from the placebo arm raises questions about the comparative effectiveness against placebo treatments. Additionally, the long-term safety profile remains to be fully established as the drug approaches regulatory review.

Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

In summary, Alumis' envudeucitinib has demonstrated promising results in its Phase 3 trials, positioning it as a potential competitor in the psoriasis treatment market. However, the company must navigate regulatory scrutiny and market dynamics as it prepares for FDA approval and commercial launch.

Fierce Biotech